Lexicon Pharmaceuticals LXRX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Lexicon Pharmaceuticals’s reported figures.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's EBITDA?
- Lexicon Pharmaceuticals (LXRX) reported EBITDA of -$886K in Q1 2026.
- How has Lexicon Pharmaceuticals's EBITDA changed year-over-year?
- Lexicon Pharmaceuticals's EBITDA increased by 96.5% year-over-year, from -$25.5M to -$886K.
- What is the long-term trend for Lexicon Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's EBITDA has grown at a -13.6% compound annual growth rate (CAGR), from -$86.8M to -$48.29M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.